Table 1. Reported toxicity data from chemoradiation trials involving immunotherapy in locally advanced, unresectable NSCLC.
| Trial | Phase | n | Treatment Arm(s) | Immune Related Events (%) | Pneumonitis (%) | Fatal pneumonitis (%) | Cardiac toxicity (%) |
|---|---|---|---|---|---|---|---|
| PACIFIC (13,14) | III | 713 | Consolidative D vs. placebo | G3+ 3.4 vs. 2.6 | 33 vs. 24; G3–4 3.4 vs. 2.6 | ~ 1 | Any cardiac disorder: 4.4 vs. 2.1 |
| LUN 14-179 (28-30) | II, single arm | 93 | Consolidative P | NA | G2+ 17.2; G3–4 5.4 | ~ 1 | NA |
| Big 10 Cancer Research Consortium 16-081 (31) | II, RCT | 20 | Consolidative N/I vs. N | N/I: G3+ 40; N: G3+ 0 | N/I: G2 0, G3+ 10; N: G2 20, G3+ 0 | 0 | NA |
| NICOLAS (32) | II, single arm | 80 | Concurrent followed by consolidative N | G5: 1.3 | 42.5; G3 10; G4 0 | 0 | CHF 2.5, pericarditis 1.3 |
| DETERRED (33) | II, 2 cohorts, not randomized | 40 | Consolidative A vs. concurrent and consolidative A |
G3+ 30 vs. 20 | G2+ 10 and 16 | 0 | ACS 10, CHF 0, pericardial effusion 10; ACS 3, CHF 3, pericardial effusion 0 |
| CINJ 031507 (34) | I | 23 | Concurrent and consolidative P | G3+ 18 | G2+ 25, G3+ 8 | 5 | NA |
A, atezolizumab; D, durvalumab; I, ipilimumab; N, nivolumab; P, pembrolizumab.